Blueprint Medicines Corp
BPMC
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
26.3% downsideOvervalued by 26.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.36 Billion |
|---|---|
| Enterprise Value | $8.36 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.07 |
| Beta | 0.83 |
| Outstanding Shares | 63,600,000 |
Return
| Return on Equity | -45.52% |
|---|---|
| Return on Assets | -13.03% |
| Return on Invested Capital | -12.51% |
Valuation & Multiples
| P/E Ratio | -165.97 |
|---|---|
| PEG | 166.9 |
| Price to Sales | 16.18 |
| Price to Book Ratio | 25.89 |
| Enterprise Value to Revenue | 14.88 |
| Enterprise Value to EBIT | -70.73 |
| Enterprise Value to Net Income | -54 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.5691▲ 88.00% |
|---|---|
| Total Calls | 973,008▼ 36.95% |
| Total Puts | 1,526,700▲ 43.57% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 101.12%▼ 6.61% |
|---|---|
| Total Invested | $8.24B▲ 35.94% |
| Investors Holding | 379▲ 9.00% |
ESG Score
No data
About Blueprint Medicines Corp
CEO: Jeffrey Albers Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policy, which is the single most critical factor for the commercial success of new pharmaceutical preparations.
Directly oversees the FDA and NIH, which are the primary regulators for drug approval and clinical trial standards for Blueprint Medicines.
Oversees intellectual property and patent law, which are fundamental to a pharmaceutical company's valuation, as well as antitrust review for potential M&A.
Regularly investigates drug pricing and healthcare quality for the elderly, creating significant headline risk and public pressure on pharmaceutical companies.